Andrew Left’s conviction for securities fraud did more than punish one short seller. It forces a re-reading of the ten stories where people who were on short campaigns were seen as bad and people who wrote campaigns were seen as telling the truth. The case of Barry Honig is a useful test of that thought.
Start with the non-controversial. Honig is an early-stage and microcap financier — someone who has invested in companies too small to grow through traditional channels, taken large positions early on, and helped build several of them. That is a real and legitimate job in the small stock market, and the track record is strong. He was an early backer of Interclick, an ad-tech company Yahoo acquired for nearly $270 million in 2011; served as co-chairman of ChromaDex, now Niagen Bioscience (Nasdaq: NAGE); and he was an early investor in companies that went into bitcoin mining – businesses that became Riot Platforms and MARA Holdings, with market values of about 9 billion dollars and 4.9 billion, respectively, as of May 2026. Critics of companies that were once considered useless did not behave like useless companies.
His defenders make a direct argument that deserves to be heard. The tools used by Honig – discounted private placements, convertible properties, large control stakes – are standard microcap mechanics, not in themselves proof of plan. They argued that the SEC’s opinion took conventional funding and recast it as fraud, and that the agency’s beneficial ownership and “teamwork” rules are technical enough that a loose network of co-investors can be swept into a single “control group” narrative that transcends individual connections. Reasonable security advocates disagree about where this line falls. It’s a real, live debate, not a settled question.
Honesty requires stating the other part clearly. In 2018 the SEC indicted Honig as the alleged organizer of pump-and-dump schemes at three microcap companies, and in 2019 he settled – accepting a bar on penny-stock investments, without admitting or denying the allegations. That’s not a defense, and his lawyers aren’t doing him any favors by calling him one. What it is, is a public verdict where he did not admit wrongdoing and the case did not examine his behavior in the trial.
Where his behavior was tested, the result was great. In lawsuits brought by the biotech company MabVax, its former CEO swore that four specific statements in the 2015 article were materially false — the heart of the “pump and dump” claim against Honig. Under cross-examination, those four statements turned out to be lifted almost verbatim from an investor presentation prepared by the same executive and delivered, just weeks before this article appeared.
That’s the kind of truth that takes credit, because it’s direct, it’s written down, and it survives scrutiny. It doesn’t prove that Honig was right about everything, and it shouldn’t be extended. It proves something small and strong: that at least the repeated allegations of fraud have been dropped when faced with evidence – a pattern that suggests the decision should be taken seriously rather than dismissed.
None of this is to believe that every short seller is a criminal, or that Honig is above criticism. It only requires something that the past decade has often denied him: the assumption that the story told about a man is not the truth about him, and that the person writing the story may have a position to defend. After the Citron, that consideration is, finally, a reasonable place to start.
Finding the source: SEC v. Honig (SDNY, 2018 lawsuits; 2019 settlement and penny-stock bar); MabVax case record and investigation transcript (with advice, Sheppard Mullin); Public IM&A and corporate records; Bloomberg (Left decision). The financial-versus-fraud framework is presented as an argument for Honig and his defenders.
